Browsing by Author "Xexemeku, F."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: Pharmacogenetic effect of CYP2B6 variation
    (Journal of Clinical Pharmacology, 2008-09) Kwara, A.; Lartey, M.; Sagoe, K.W.; Xexemeku, F.; Kenu, E.; Oliver-Commey, J.; Boima, V.; Sagoe, A.; Boamah, I.; Greenblatt, D.J.; Court, M.H.
    The goal of this study was to determine the effect of CYP2B6 genetic variation on the steady-state pharmacokinetics of efavirenz (600 mg/d) in TB/HIV co-infected patients receiving concomitant rifampin, a potent CYP inducer. In the 26 patients studied, CYP2B6 c.516GG, GT, and TT genotype frequencies were 0.27, 0.50, and 0.23, respectively. Mean plasma efavirenz area under the curve was significantly higher in patients with CYP2B6 c.516TT than in those with GT (107 vs 27.6 μg·h/mL, P <.0001) or GG genotype (107 vs 23.0 μg· h/mL, P <.0001). Apparent oral clearance (CL/F) was significantly lower in patients with CYP2B6 c.516TT than in those with GT genotype (2.1 vs 8.4 mL/min/kg, P < 0.0001) and GG genotype (2.1 vs 9.9 mL/min/kg, P <.0001). No differences in efavirenz exposure or CL/F existed between patients with CYP2B6 c.516GT and GG genotypes. Our results indicate that CYP2B6 c.516TT genotype can be used to identify efavirenz poor metabolizers in patients co-treated with rifampin. © 2008 the American College of Clinical Pharmacology.
  • No Thumbnail Available
    Item
    Viral decay rates are similar in HIV-infected patients with and without TB coinfection during treatment with an efavirenz-based regimen
    (Clinical Infectious Diseases, 2011-02) Lartey, M.; Sagoe, K.W.; Yang, H.; Kenu, E.; Xexemeku, F.; Oliver-Commey, J.; Boima, V.; Seshie, M.; Sagoe, A.; Mingle, J.A.A.; Flanigan, T.P.; Wu, H.; Kwara, A.
    Viral decay rates during efavirenz-based therapy were compared between human immunodeficiency virus (HIV)-infected patients without tuberculosis (n = 40) and those with tuberculosis coinfection who were receiving concurrent antituberculous therapy (n = 34). Phase I and II viral decay rates were similar in the 2 groups (P >.05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment. © The Author 2011.